https://www.selleckchem.com/products/nsc16168.html
OBJECTIVE We aimed to assess the efficacy and benefit-risk profile of pregabalin (PGN) to reduce the clinical signs of central neuropathic pain (CNeP) as reflected by scratching episodes in dogs with symptomatic syringomyelia (SM). STUDY DESIGN Randomized, double-blind, placebo-controlled crossover study. ANIMALS A total of 12 client-owned Cavalier King Charles Spaniels (age, 1.1-7.4 years, bodyweight, 8.2-10.8 kg) with magnetic resonance imaging-confirmed SM and clinical signs of CNeP. METHODS Dogs were randomized to either PGN 150 mg
Like
Comment
Share
